메뉴 건너뛰기




Volumn 14, Issue 10, 2017, Pages 595-610

Clinical utility of gene-expression signatures in early stage breast cancer

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; LETROZOLE; METHOTREXATE; PACLITAXEL; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; TRANSCRIPTOME; TUMOR MARKER;

EID: 85030612526     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2017.74     Document Type: Review
Times cited : (198)

References (110)
  • 2
    • 84877028141 scopus 로고    scopus 로고
    • Comprehensive molecular portraits of human breast tumours
    • Cancer Genome Atlas Network
    • Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
    • (2012) Nature , vol.490 , pp. 61-70
  • 3
    • 0035881617 scopus 로고    scopus 로고
    • Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns
    • Gruvberger, S. et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 61, 5979-5984 (2001).
    • (2001) Cancer Res. , vol.61 , pp. 5979-5984
    • Gruvberger, S.1
  • 4
    • 0035845511 scopus 로고    scopus 로고
    • Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
    • Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
    • (2001) Proc. Natl Acad. Sci. USA , vol.98 , pp. 10869-10874
    • Sorlie, T.1
  • 6
    • 77954526150 scopus 로고    scopus 로고
    • American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
    • Hammond, M. E. et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28, 2784-2795 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , pp. 2784-2795
    • Hammond, M.E.1
  • 7
    • 84890254448 scopus 로고    scopus 로고
    • Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
    • Wolff, A. C. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 31, 3997-4013 (2013).
    • (2013) J. Clin. Oncol. , vol.31 , pp. 3997-4013
    • Wolff, A.C.1
  • 8
    • 2942623615 scopus 로고    scopus 로고
    • Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer
    • Esteva, F. J. Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. Oncologist 9, 4-9 (2004).
    • (2004) Oncologist , vol.9 , pp. 4-9
    • Esteva, F.J.1
  • 9
    • 76549090842 scopus 로고    scopus 로고
    • Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
    • Morrow, P. K., Zambrana, F. & Esteva, F. J. Recent advances in systemic therapy: advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res. 11, 207 (2009).
    • (2009) Breast Cancer Res. , vol.11 , pp. 207
    • Morrow, P.K.1    Zambrana, F.2    Esteva, F.J.3
  • 10
    • 0034470522 scopus 로고    scopus 로고
    • Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer
    • Fornier, M., Esteva, F. J. & Seidman, A. D. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin. Oncol. 27, 38-45 (2000).
    • (2000) Semin. Oncol. , vol.27 , pp. 38-45
    • Fornier, M.1    Esteva, F.J.2    Seidman, A.D.3
  • 11
    • 84905841417 scopus 로고    scopus 로고
    • Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update
    • Burstein, H. J. et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J. Clin. Oncol. 32, 2255-2269 (2014).
    • (2014) J. Clin. Oncol. , vol.32 , pp. 2255-2269
    • Burstein, H.J.1
  • 12
    • 0035865149 scopus 로고    scopus 로고
    • Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer
    • Ravdin, P. M. et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J. Clin. Oncol. 19, 980-991 (2001).
    • (2001) J. Clin. Oncol. , vol.19 , pp. 980-991
    • Ravdin, P.M.1
  • 13
    • 84926139019 scopus 로고    scopus 로고
    • Biological subtypes of breast cancer: Prognostic and therapeutic implications
    • Yersal, O. & Barutca, S. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J. Clin. Oncol. 5, 412-424 (2014).
    • (2014) World J. Clin. Oncol. , vol.5 , pp. 412-424
    • Yersal, O.1    Barutca, S.2
  • 14
    • 19344364880 scopus 로고    scopus 로고
    • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
    • Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
    • (2005) Lancet , vol.365 , pp. 1687-1717
  • 15
    • 85203363507 scopus 로고    scopus 로고
    • Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials
    • Early Breast Cancer Trialists' Collaborative Group et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771-784 (2011).
    • (2011) Lancet , vol.378 , pp. 771-784
  • 16
    • 84856636292 scopus 로고    scopus 로고
    • Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials
    • Early Breast Cancer Trialists' Collaborative Group et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379, 432-444 (2012).
    • (2012) Lancet , vol.379 , pp. 432-444
  • 17
    • 0034680102 scopus 로고    scopus 로고
    • Molecular portraits of human breast tumours
    • Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
    • (2000) Nature , vol.406 , pp. 747-752
    • Perou, C.M.1
  • 18
    • 66849140730 scopus 로고    scopus 로고
    • Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer
    • Cheang, M. C. et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl Cancer Inst. 101, 736-750 (2009).
    • (2009) J. Natl Cancer Inst. , vol.101 , pp. 736-750
    • Cheang, M.C.1
  • 19
    • 0042838307 scopus 로고    scopus 로고
    • Breast cancer classification and prognosis based on gene expression profiles from a population-based study
    • Sotiriou, C. et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 100, 10393-10398 (2003).
    • (2003) Proc. Natl Acad. Sci. USA , vol.100 , pp. 10393-10398
    • Sotiriou, C.1
  • 20
    • 23844549918 scopus 로고    scopus 로고
    • Breast cancer molecular subtypes respond differently to preoperative chemotherapy
    • Rouzier, R. et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11, 5678-5685 (2005).
    • (2005) Clin. Cancer Res. , vol.11 , pp. 5678-5685
    • Rouzier, R.1
  • 21
    • 78049308800 scopus 로고    scopus 로고
    • Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
    • Prat, A. et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12, R68 (2010).
    • (2010) Breast Cancer Res. , vol.12 , pp. R68
    • Prat, A.1
  • 22
    • 84963558666 scopus 로고    scopus 로고
    • Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline
    • Harris, L. N. et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 34, 1134-1150 (2016).
    • (2016) J. Clin. Oncol. , vol.34 , pp. 1134-1150
    • Harris, L.N.1
  • 23
    • 59849108152 scopus 로고    scopus 로고
    • The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: Methods of the EGAPP Working Group
    • Teutsch, S. M. et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. Genet. Med. 11, 3-14 (2009).
    • (2009) Genet. Med. , vol.11 , pp. 3-14
    • Teutsch, S.M.1
  • 24
    • 77951482885 scopus 로고    scopus 로고
    • Outcomes of interest in evidence-based evaluations of genetic tests
    • Botkin, J. R. et al. Outcomes of interest in evidence-based evaluations of genetic tests. Genet. Med. 12, 228-235 (2010).
    • (2010) Genet. Med. , vol.12 , pp. 228-235
    • Botkin, J.R.1
  • 25
    • 19944422061 scopus 로고    scopus 로고
    • A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    • Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).
    • (2004) N. Engl. J. Med. , vol.351 , pp. 2817-2826
    • Paik, S.1
  • 26
    • 1842573771 scopus 로고    scopus 로고
    • Tumor gene expression and prognosis in breast cancer: Multi-gene RT-PCR assay of paraffin-embedded tissue [abstract]
    • Esteban, J. et al. Tumor gene expression and prognosis in breast cancer: multi-gene RT-PCR assay of paraffin-embedded tissue [abstract]. Proc. Am. Soc. Clin. Oncol. 22, 850 (2003).
    • (2003) Proc. Am. Soc. Clin. Oncol. , vol.22 , pp. 850
    • Esteban, J.1
  • 27
    • 1042284395 scopus 로고    scopus 로고
    • Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer patients with 10 or more positive nodes: High throughout RT-PCR assay of paraffin-embedded tumor tissues [abstract]
    • Cobleigh, M. A. et al. Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer patients with 10 or more positive nodes: high throughout RT-PCR assay of paraffin-embedded tumor tissues [abstract]. Proc. Am. Soc. Clin. Oncol. 22, 850 (2003).
    • (2003) Proc. Am. Soc. Clin. Oncol. , vol.22 , pp. 850
    • Cobleigh, M.A.1
  • 28
    • 1842573772 scopus 로고    scopus 로고
    • Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients - NSABP studies B-20 and B-14
    • Paik, S. et al. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients - NSABP studies B-20 and B-14. Breast Cancer Res. Treat. 82, A16 (2003).
    • (2003) Breast Cancer Res. Treat. , vol.82 , pp. A16
    • Paik, S.1
  • 29
    • 20944432470 scopus 로고    scopus 로고
    • Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy
    • Esteva, F. J. et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin. Cancer Res. 11, 3315-3319 (2005).
    • (2005) Clin. Cancer Res. , vol.11 , pp. 3315-3319
    • Esteva, F.J.1
  • 30
    • 33744814477 scopus 로고    scopus 로고
    • Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
    • Paik, S. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726-3734 (2006).
    • (2006) J. Clin. Oncol. , vol.24 , pp. 3726-3734
    • Paik, S.1
  • 31
    • 51749093141 scopus 로고    scopus 로고
    • Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197
    • Goldstein, L. J. et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J. Clin. Oncol. 26, 4092-4099 (2008).
    • (2008) J. Clin. Oncol. , vol.26 , pp. 4092-4099
    • Goldstein, L.J.1
  • 32
    • 51649110952 scopus 로고    scopus 로고
    • Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features
    • Goldstein, L. J. et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J. Clin. Oncol. 26, 4063-4071 (2008).
    • (2008) J. Clin. Oncol. , vol.26 , pp. 4063-4071
    • Goldstein, L.J.1
  • 33
    • 77951637777 scopus 로고    scopus 로고
    • Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study
    • Dowsett, M. et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J. Clin. Oncol. 28, 1829-1834 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , pp. 1829-1834
    • Dowsett, M.1
  • 34
    • 84928572844 scopus 로고    scopus 로고
    • Biomarker validation and testing
    • Hayes, D. F. Biomarker validation and testing. Mol. Oncol. 9, 960-966 (2015).
    • (2015) Mol. Oncol. , vol.9 , pp. 960-966
    • Hayes, D.F.1
  • 35
    • 33750895236 scopus 로고    scopus 로고
    • TAILORx: Trial assigning individualized options for treatment (Rx)
    • Sparano, J. A. TAILORx: trial assigning individualized options for treatment (Rx). Clin. Breast Cancer 7, 347-350 (2006).
    • (2006) Clin. Breast Cancer , vol.7 , pp. 347-350
    • Sparano, J.A.1
  • 36
    • 84947730258 scopus 로고    scopus 로고
    • Prospective validation of a 21-gene expression assay in breast cancer
    • Sparano, J. A. et al. Prospective validation of a 21-gene expression assay in breast cancer. N. Engl. J. Med. 373, 2005-2014 (2015).
    • (2015) N. Engl. J. Med. , vol.373 , pp. 2005-2014
    • Sparano, J.A.1
  • 37
    • 62449131093 scopus 로고    scopus 로고
    • Supervised risk predictor of breast cancer based on intrinsic subtypes
    • Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , pp. 1160-1167
    • Parker, J.S.1
  • 38
    • 83455203587 scopus 로고    scopus 로고
    • NanoStriDE: Normalization and differential expression analysis of NanoString nCounter data
    • Brumbaugh, C. D., Kim, H. J., Giovacchini, M. & Pourmand, N. NanoStriDE: normalization and differential expression analysis of NanoString nCounter data. BMC Bioinformatics 12, 479 (2011).
    • (2011) BMC Bioinformatics , vol.12 , pp. 479
    • Brumbaugh, C.D.1    Kim, H.J.2    Giovacchini, M.3    Pourmand, N.4
  • 39
    • 33749030177 scopus 로고    scopus 로고
    • Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
    • Hess, K. R. et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 24, 4236-4244 (2006).
    • (2006) J. Clin. Oncol. , vol.24 , pp. 4236-4244
    • Hess, K.R.1
  • 40
    • 0035224451 scopus 로고    scopus 로고
    • Expression of ErbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry
    • Esteva, F. J. et al. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol. Oncol. Res. 7, 171-177 (2001).
    • (2001) Pathol. Oncol. Res. , vol.7 , pp. 171-177
    • Esteva, F.J.1
  • 41
    • 78049453780 scopus 로고    scopus 로고
    • A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer
    • Nielsen, T. O. et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin. Cancer Res. 16, 5222-5232 (2010).
    • (2010) Clin. Cancer Res. , vol.16 , pp. 5222-5232
    • Nielsen, T.O.1
  • 42
    • 84893424611 scopus 로고    scopus 로고
    • Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: Using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
    • Gnant, M. et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann. Oncol. 25, 339-345 (2014).
    • (2014) Ann. Oncol. , vol.25 , pp. 339-345
    • Gnant, M.1
  • 43
    • 18244409687 scopus 로고    scopus 로고
    • Gene expression profiling predicts clinical outcome of breast cancer
    • van 't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
    • (2002) Nature , vol.415 , pp. 530-536
    • Van 't Veer, L.J.1
  • 44
    • 0037137519 scopus 로고    scopus 로고
    • A gene-expression signature as a predictor of survival in breast cancer
    • van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
    • (2002) N. Engl. J. Med. , vol.347 , pp. 1999-2009
    • Van De Vijver, M.J.1
  • 45
    • 84894092094 scopus 로고    scopus 로고
    • Long-term impact of the 70-gene signature on breast cancer outcome
    • Drukker, C. A. et al. Long-term impact of the 70-gene signature on breast cancer outcome. Breast Cancer Res. Treat. 143, 587-592 (2014).
    • (2014) Breast Cancer Res. Treat. , vol.143 , pp. 587-592
    • Drukker, C.A.1
  • 46
    • 33748693297 scopus 로고    scopus 로고
    • Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
    • Buyse, M. et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst. 98, 1183-1192 (2006).
    • (2006) J. Natl Cancer Inst. , vol.98 , pp. 1183-1192
    • Buyse, M.1
  • 47
    • 84878857125 scopus 로고    scopus 로고
    • A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
    • Drukker, C. A. et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int. J. Cancer 133, 929-936 (2013).
    • (2013) Int. J. Cancer , vol.133 , pp. 929-936
    • Drukker, C.A.1
  • 48
    • 20444433297 scopus 로고    scopus 로고
    • Kwaliteitsinstituut voor de Gezondheidszorg CBO VvlK Richtlijn Behandeling van het Mammacarcinoom [Dutch]
    • Kwaliteitsinstituut voor de Gezondheidszorg CBO VvlK. Adjuvante Systemische Therapie voor het Operabel Mammacarcinoom. Richtlijn Behandeling van het Mammacarcinoom [Dutch]. 46-70 (2004).
    • (2004) Adjuvante Systemische Therapie voor Het Operabel Mammacarcinoom , pp. 46-70
  • 49
    • 80052418906 scopus 로고    scopus 로고
    • Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice
    • Bueno-De-Mesquita, J. M., Sonke, G. S., van de Vijver, M. J. & Linn, S. C. Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice. Ann. Oncol. 22, 2021-2030 (2011).
    • (2011) Ann. Oncol. , vol.22 , pp. 2021-2030
    • Bueno-De-Mesquita, J.M.1    Sonke, G.S.2    Van De Vijver, M.J.3    Linn, S.C.4
  • 50
    • 49649114805 scopus 로고    scopus 로고
    • Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort
    • Wittner, B. S. et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin. Cancer Res. 14, 2988-2993 (2008).
    • (2008) Clin. Cancer Res. , vol.14 , pp. 2988-2993
    • Wittner, B.S.1
  • 51
    • 84912011010 scopus 로고    scopus 로고
    • Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: A pooled analysis
    • Drukker, C. A. et al. Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis. Breast Cancer Res. Treat. 148, 599-613 (2014).
    • (2014) Breast Cancer Res. Treat. , vol.148 , pp. 599-613
    • Drukker, C.A.1
  • 52
    • 67649183386 scopus 로고    scopus 로고
    • The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study
    • Mook, S. et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res. Treat. 116, 295-302 (2009).
    • (2009) Breast Cancer Res. Treat. , vol.116 , pp. 295-302
    • Mook, S.1
  • 53
    • 77950862535 scopus 로고    scopus 로고
    • The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age
    • Mook, S. et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann. Oncol. 21, 717-722 (2010).
    • (2010) Ann. Oncol. , vol.21 , pp. 717-722
    • Mook, S.1
  • 54
    • 84884127326 scopus 로고    scopus 로고
    • Additional prognostic value of the 70-gene signature (MammaPrint®) among breast cancer patients with 4-9 positive lymph nodes
    • Saghatchian, M. et al. Additional prognostic value of the 70-gene signature (MammaPrint®) among breast cancer patients with 4-9 positive lymph nodes. Breast 22, 682-690 (2013).
    • (2013) Breast , vol.22 , pp. 682-690
    • Saghatchian, M.1
  • 55
    • 84894033527 scopus 로고    scopus 로고
    • MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue
    • Sapino, A. et al. MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue. J. Mol. Diagn. 16, 190-197 (2014).
    • (2014) J. Mol. Diagn. , vol.16 , pp. 190-197
    • Sapino, A.1
  • 56
    • 79951818662 scopus 로고    scopus 로고
    • Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue
    • Mittempergher, L. et al. Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue. PLoS ONE 6, e17163 (2011).
    • (2011) PLoS ONE , vol.6 , pp. e17163
    • Mittempergher, L.1
  • 57
    • 84984697640 scopus 로고    scopus 로고
    • 70-gene signature as an aid to treatment decisions in early-stage breast cancer
    • Cardoso, F. et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N. Engl. J. Med. 375, 717-729 (2016).
    • (2016) N. Engl. J. Med. , vol.375 , pp. 717-729
    • Cardoso, F.1
  • 58
    • 2942578063 scopus 로고    scopus 로고
    • A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen
    • Ma, X. J. et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5, 607-616 (2004).
    • (2004) Cancer Cell , vol.5 , pp. 607-616
    • Ma, X.J.1
  • 59
    • 52049095087 scopus 로고    scopus 로고
    • A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer
    • Ma, X. J. et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin. Cancer Res. 14, 2601-2608 (2008).
    • (2008) Clin. Cancer Res. , vol.14 , pp. 2601-2608
    • Ma, X.J.1
  • 60
    • 79957617088 scopus 로고    scopus 로고
    • Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial
    • Jerevall, P. L. et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br. J. Cancer 104, 1762-1769 (2011).
    • (2011) Br. J. Cancer , vol.104 , pp. 1762-1769
    • Jerevall, P.L.1
  • 61
    • 84874931531 scopus 로고    scopus 로고
    • HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease
    • Habel, L. A. et al. HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease. Breast Cancer Res. 15, R24 (2013).
    • (2013) Breast Cancer Res. , vol.15 , pp. R24
    • Habel, L.A.1
  • 62
    • 7444259675 scopus 로고    scopus 로고
    • A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
    • Goss, P. E. et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349, 1793-1802 (2003).
    • (2003) N. Engl. J. Med. , vol.349 , pp. 1793-1802
    • Goss, P.E.1
  • 64
    • 84880515409 scopus 로고    scopus 로고
    • Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker
    • Sgroi, D. C. et al. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J. Natl Cancer Inst. 105, 1036-1042 (2013).
    • (2013) J. Natl Cancer Inst. , vol.105 , pp. 1036-1042
    • Sgroi, D.C.1
  • 65
    • 80052845090 scopus 로고    scopus 로고
    • A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors
    • Filipits, M. et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin. Cancer Res. 17, 6012-6020 (2011).
    • (2011) Clin. Cancer Res. , vol.17 , pp. 6012-6020
    • Filipits, M.1
  • 66
    • 84866973653 scopus 로고    scopus 로고
    • Decentral gene expression analysis: Analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test
    • Kronenwett, R. et al. Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test. BMC Cancer 12, 456 (2012).
    • (2012) BMC Cancer , vol.12 , pp. 456
    • Kronenwett, R.1
  • 67
    • 84874570581 scopus 로고    scopus 로고
    • EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
    • Dubsky, P. et al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann. Oncol. 24, 640-647 (2013).
    • (2013) Ann. Oncol. , vol.24 , pp. 640-647
    • Dubsky, P.1
  • 68
    • 84890426904 scopus 로고    scopus 로고
    • The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2-breast cancer patients
    • Dubsky, P. et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2-breast cancer patients. Br. J. Cancer 109, 2959-2964 (2013).
    • (2013) Br. J. Cancer , vol.109 , pp. 2959-2964
    • Dubsky, P.1
  • 69
    • 0037445117 scopus 로고    scopus 로고
    • Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6
    • Schmid, M. et al. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. J. Clin. Oncol. 21, 984-990 (2003).
    • (2003) J. Clin. Oncol. , vol.21 , pp. 984-990
    • Schmid, M.1
  • 70
    • 23444446523 scopus 로고    scopus 로고
    • Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial
    • Jakesz, R. et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366, 455-462 (2005).
    • (2005) Lancet , vol.366 , pp. 455-462
    • Jakesz, R.1
  • 71
    • 84902257708 scopus 로고    scopus 로고
    • Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2-breast cancer patients: Results from the GEICAM 9906 trial
    • Martin, M. et al. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2-breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Res. 16, R38 (2014).
    • (2014) Breast Cancer Res. , vol.16 , pp. R38
    • Martin, M.1
  • 72
    • 81155133281 scopus 로고    scopus 로고
    • Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer
    • Cuzick, J. et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J. Clin. Oncol. 29, 4273-4278 (2011).
    • (2011) J. Clin. Oncol. , vol.29 , pp. 4273-4278
    • Cuzick, J.1
  • 73
    • 84891459472 scopus 로고    scopus 로고
    • An international Ki67 reproducibility study
    • Polley, M. Y. et al. An international Ki67 reproducibility study. J. Natl Cancer Inst. 105, 1897-1906 (2013).
    • (2013) J. Natl Cancer Inst. , vol.105 , pp. 1897-1906
    • Polley, M.Y.1
  • 74
    • 33144462268 scopus 로고    scopus 로고
    • Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis
    • Sotiriou, C. et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Inst. 98, 262-272 (2006).
    • (2006) J. Natl Cancer Inst. , vol.98 , pp. 262-272
    • Sotiriou, C.1
  • 75
    • 34247145491 scopus 로고    scopus 로고
    • Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
    • Loi, S. et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J. Clin. Oncol. 25, 1239-1246 (2007).
    • (2007) J. Clin. Oncol. , vol.25 , pp. 1239-1246
    • Loi, S.1
  • 76
    • 67650327607 scopus 로고    scopus 로고
    • Genomic grade index is associated with response to chemotherapy in patients with breast cancer
    • Liedtke, C. et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J. Clin. Oncol. 27, 3185-3191 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , pp. 3185-3191
    • Liedtke, C.1
  • 77
    • 33746910265 scopus 로고    scopus 로고
    • Concordance among gene-expression-based predictors for breast cancer
    • Fan, C. et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355, 560-569 (2006).
    • (2006) N. Engl. J. Med. , vol.355 , pp. 560-569
    • Fan, C.1
  • 78
    • 0037478605 scopus 로고    scopus 로고
    • Repeated observation of breast tumor subtypes in independent gene expression data sets
    • Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418-8423 (2003).
    • (2003) Proc. Natl Acad. Sci. USA , vol.100 , pp. 8418-8423
    • Sorlie, T.1
  • 79
    • 20144386127 scopus 로고    scopus 로고
    • Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival
    • Chang, H. Y. et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl Acad. Sci. USA 102, 3738-3743 (2005).
    • (2005) Proc. Natl Acad. Sci. USA , vol.102 , pp. 3738-3743
    • Chang, H.Y.1
  • 80
    • 19344363035 scopus 로고    scopus 로고
    • Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds
    • Chang, H. Y. et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2, E7 (2004).
    • (2004) PLoS Biol. , vol.2 , pp. E7
    • Chang, H.Y.1
  • 81
    • 58149330982 scopus 로고    scopus 로고
    • Meta-analysis of gene expression profiles in breast cancer: Toward a unified understanding of breast cancer subtyping and prognosis signatures
    • Wirapati, P. et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 10, R65 (2008).
    • (2008) Breast Cancer Res. , vol.10 , pp. R65
    • Wirapati, P.1
  • 82
    • 84884762173 scopus 로고    scopus 로고
    • Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy
    • Dowsett, M. et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J. Clin. Oncol. 31, 2783-2790 (2013).
    • (2013) J. Clin. Oncol. , vol.31 , pp. 2783-2790
    • Dowsett, M.1
  • 83
    • 78449291165 scopus 로고    scopus 로고
    • Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers
    • Kelly, C. M. et al. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 116, 5161-5167 (2010).
    • (2010) Cancer , vol.116 , pp. 5161-5167
    • Kelly, C.M.1
  • 84
    • 84860150463 scopus 로고    scopus 로고
    • Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 Breast Cancer Intrinsic Classifier in early-stage estrogen receptor-positive breast cancer
    • Kelly, C. M. et al. Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 Breast Cancer Intrinsic Classifier in early-stage estrogen receptor-positive breast cancer. Oncologist 17, 492-498 (2012).
    • (2012) Oncologist , vol.17 , pp. 492-498
    • Kelly, C.M.1
  • 85
    • 84884704047 scopus 로고    scopus 로고
    • Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: A prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population
    • Sgroi, D. C. et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 14, 1067-1076 (2013).
    • (2013) Lancet Oncol. , vol.14 , pp. 1067-1076
    • Sgroi, D.C.1
  • 86
    • 85003047281 scopus 로고    scopus 로고
    • The Genomic Grade assay compared with Ki67 to determine risk of distant breast cancer recurrence
    • Ignatiadis, M. et al. The Genomic Grade assay compared with Ki67 to determine risk of distant breast cancer recurrence. JAMA Oncol. 2, 217-224 (2016).
    • (2016) JAMA Oncol. , vol.2 , pp. 217-224
    • Ignatiadis, M.1
  • 87
    • 29544433211 scopus 로고    scopus 로고
    • A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
    • Breast International Group (BIG) 1-98 Collaborative Group et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353, 2747-2757 (2005).
    • (2005) N. Engl. J. Med. , vol.353 , pp. 2747-2757
  • 88
    • 84989180539 scopus 로고    scopus 로고
    • Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: No test is more equal than the others
    • Bartlett, J. M. et al. Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others. J. Natl Cancer Inst. 108, djw050 (2016).
    • (2016) J. Natl Cancer Inst. , vol.108 , pp. djw050
    • Bartlett, J.M.1
  • 89
    • 85023764496 scopus 로고    scopus 로고
    • Comprehensive comparison of prognostic signatures for breast cancer in TransATAC [abstract]
    • Abstr. S6-05
    • Sestack, I. et al. Comprehensive comparison of prognostic signatures for breast cancer in TransATAC [abstract]. 2016 San Antonio Breast Cancer Symposium (SABCS). Abstr. S6-05 (2016).
    • (2016) 2016 San Antonio Breast Cancer Symposium (SABCS)
    • Sestack, I.1
  • 90
    • 18444383684 scopus 로고    scopus 로고
    • Population-based validation of the prognostic model ADJUVANT! for early breast cancer
    • Bajdik, I. A. et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J. Clin. Oncol. 23, 2716-2725 (2005).
    • (2005) J. Clin. Oncol. , vol.23 , pp. 2716-2725
    • Bajdik, I.A.1
  • 91
    • 84887989400 scopus 로고    scopus 로고
    • Prospective cost-effectiveness analysis of genomic profiling in breast cancer
    • Retel, V. P. et al. Prospective cost-effectiveness analysis of genomic profiling in breast cancer. Eur. J. Cancer 49, 3773-3779 (2013).
    • (2013) Eur. J. Cancer , vol.49 , pp. 3773-3779
    • Retel, V.P.1
  • 92
    • 84863723973 scopus 로고    scopus 로고
    • Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer
    • Lamond, N. W., Skedgel, C., Rayson, D., Lethbridge, L. & Younis, T. Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Res. Treat. 133, 1115-1123 (2012).
    • (2012) Breast Cancer Res. Treat. , vol.133 , pp. 1115-1123
    • Lamond, N.W.1    Skedgel, C.2    Rayson, D.3    Lethbridge, L.4    Younis, T.5
  • 93
    • 33947196825 scopus 로고    scopus 로고
    • Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: An economic analysis based on prognostic and predictive validation studies
    • Lyman, G. H., Cosler, L. E., Kuderer, N. M. & Hornberger, J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 109, 1011-1018 (2007).
    • (2007) Cancer , vol.109 , pp. 1011-1018
    • Lyman, G.H.1    Cosler, L.E.2    Kuderer, N.M.3    Hornberger, J.4
  • 94
    • 79957823551 scopus 로고    scopus 로고
    • Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer
    • Chen, E., Tong, K. B. & Malin, J. L. Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer. Am. J. Manag. Care 16, e333-e342 (2010).
    • (2010) Am. J. Manag. Care , vol.16 , pp. e333-e342
    • Chen, E.1    Tong, K.B.2    Malin, J.L.3
  • 95
    • 77951938304 scopus 로고    scopus 로고
    • Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer
    • Retel, V. P. et al. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. Eur. J. Cancer 46, 1382-1391 (2010).
    • (2010) Eur. J. Cancer , vol.46 , pp. 1382-1391
    • Retel, V.P.1
  • 96
    • 84885136402 scopus 로고    scopus 로고
    • Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: A systematic review and cost-effectiveness analysis
    • Ward, S. et al. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis. Health Technol. Assess. 17, 1-302 (2013).
    • (2013) Health Technol. Assess. , vol.17 , pp. 1-302
    • Ward, S.1
  • 97
    • 84879767780 scopus 로고    scopus 로고
    • Multigene assays and molecular markers in breast cancer: Systematic review of health economic analyses
    • Rouzier, R. et al. Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. Breast Cancer Res. Treat. 139, 621-637 (2013).
    • (2013) Breast Cancer Res. Treat. , vol.139 , pp. 621-637
    • Rouzier, R.1
  • 98
    • 84867334350 scopus 로고    scopus 로고
    • Cost effectiveness of gene expression profiling for early stage breast cancer: A decision-analytic model
    • Yang, M., Rajan, S. & Issa, A. M. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model. Cancer 118, 5163-5170 (2012).
    • (2012) Cancer , vol.118 , pp. 5163-5170
    • Yang, M.1    Rajan, S.2    Issa, A.M.3
  • 99
    • 0029866092 scopus 로고    scopus 로고
    • On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993
    • Griffin, A. M. et al. On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann. Oncol. 7, 189-195 (1996).
    • (1996) Ann. Oncol. , vol.7 , pp. 189-195
    • Griffin, A.M.1
  • 100
    • 84874572643 scopus 로고    scopus 로고
    • Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group consensus statement
    • Azim, H. A. Jr et al. Utility of prognostic genomic tests in breast cancer practice: the IMPAKT 2012 Working Group consensus statement. Ann. Oncol. 24, 647-654 (2013).
    • (2013) Ann. Oncol. , vol.24 , pp. 647-654
    • Azim, H.A.1
  • 101
    • 36849069347 scopus 로고    scopus 로고
    • American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
    • Harris, L. et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25, 5287-5312 (2007).
    • (2007) J. Clin. Oncol. , vol.25 , pp. 5287-5312
    • Harris, L.1
  • 102
    • 84876691969 scopus 로고    scopus 로고
    • Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients
    • Harbeck, N. et al. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur. J. Cancer 49, 1825-1835 (2013).
    • (2013) Eur. J. Cancer , vol.49 , pp. 1825-1835
    • Harbeck, N.1
  • 103
    • 58149183234 scopus 로고    scopus 로고
    • Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials
    • Ross, D. T. et al. Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials. Clin. Cancer Res. 14, 6602-6609 (2008).
    • (2008) Clin. Cancer Res. , vol.14 , pp. 6602-6609
    • Ross, D.T.1
  • 104
    • 51349088017 scopus 로고    scopus 로고
    • Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes
    • Desmedt, C. et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 14, 5158-5165 (2008).
    • (2008) Clin. Cancer Res. , vol.14 , pp. 5158-5165
    • Desmedt, C.1
  • 105
    • 84875722651 scopus 로고    scopus 로고
    • Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98
    • Loi, S. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol. 31, 860-867 (2013).
    • (2013) J. Clin. Oncol. , vol.31 , pp. 860-867
    • Loi, S.1
  • 106
    • 84905178989 scopus 로고    scopus 로고
    • Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial
    • Loi, S. et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann. Oncol. 25, 1544-1550 (2014).
    • (2014) Ann. Oncol. , vol.25 , pp. 1544-1550
    • Loi, S.1
  • 107
    • 72149104757 scopus 로고    scopus 로고
    • Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: A phase 3, open-label, randomised controlled trial
    • Albain, K. S. et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374, 2055-2063 (2009).
    • (2009) Lancet , vol.374 , pp. 2055-2063
    • Albain, K.S.1
  • 109
    • 0038662715 scopus 로고    scopus 로고
    • Participation of patients 65 years of age or older in cancer clinical trials
    • Lewis, J. H. et al. Participation of patients 65 years of age or older in cancer clinical trials. J. Clin. Oncol. 21, 1383-1389 (2003).
    • (2003) J. Clin. Oncol. , vol.21 , pp. 1383-1389
    • Lewis, J.H.1
  • 110
    • 84858165551 scopus 로고    scopus 로고
    • The EORTC Cancer in the Elderly Task Force, a Protostar for EORTC's future
    • Wildiers, H. et al. The EORTC Cancer in the Elderly Task Force, a Protostar for EORTC's future. Eur. J. Cancer 10, 34-38 (2012).
    • (2012) Eur. J. Cancer , vol.10 , pp. 34-38
    • Wildiers, H.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.